GRPH

Graphite Bio, Inc. [GRPH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GRPH Stock Summary

Top 10 Correlated ETFs

GRPH


Top 10 Correlated Stocks

GRPH


In the News

01:32 28 Mar 2024 GRPH

What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock

Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

02:08 28 Mar 2024 GRPH

Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs

About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state government filings show.

11:17 28 Mar 2024 GRPH

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

07:33 28 Mar 2024 GRPH

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

09:19 28 Mar 2024 GRPH

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prime candidate for the Compounding Healthcare “Bio Boom” Portfolio.

10:14 28 Mar 2024 GRPH

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

02:37 28 Mar 2024 GRPH

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.

09:33 28 Mar 2024 GRPH

Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:21 28 Mar 2024 GRPH

SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in the NextGen Bio “Class of 2022.

04:26 28 Mar 2024 GRPH

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio: An Important Stock To Track In The Gene Editing Space

GRPH Financial details

Company Rating
Neutral
Market Cap
185.19M
Income
-122.14M
Revenue
10.24M
Book val./share
3.16
Cash/share
3.2
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
25 Mar 2024
P/E
-1.33
Forward P/E
-7.95
PEG
-0.62
P/S
-
P/B
0.79
P/C
0.99
P/FCF
-2.09
Quick Ratio
18.66
Current Ratio
19.05
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-2.14
EPS next Y
-0.4
EPS next Q
-0.11
EPS this Y
24.43%
EPS next Y
-81.31%
EPS next 5Y
-81.31%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.56%
-
-
-
-
SMA20
-14.29%
SMA50
-5.26%
SMA100
5.88%
Inst Own
28.9%
Inst Trans
0.51%
ROA
-46%
ROE
-49%
ROC
-0.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
58.24M
Shs Float
2.38M
-
-
-
-
Target Price
4
52W Range
2.01-4.26
52W High
-20.5%
52W Low
+59%
RSI
38
Rel Volume
1.08
Avg Volume
278.47K
Volume
299.41K
Perf Week
-86.4%
Perf Month
-84.7%
Perf Quarter
-81.61%
Perf Half Y
-82.25%
-
-
-
-
Beta
0.196
-
-
Volatility
8.65%, 4.98%
Prev Close
-85.71%
Price
3.18
Change
-85.71%

GRPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.01-0.4-2.06-1.76-2.19
Operating cash flow per share
0-0.26-1.83-1.6-1.58
Free cash flow per share
0-0.3-2.03-1.72-1.77
Cash per share
00.5813.044.893.26
Book value per share
-0.15-1.9113.285.43.22
Tangible book value per share
-0.15-1.9113.285.43.22
Share holders equity per share
-0.15-1.9113.285.43.22
Interest debt per share
0.1600.390.190.01
Market cap
270.61M632.46M359.47M182.18M149.38M
Enterprise value
272.81M612.67M-6.23M140.24M-36.12M
P/E ratio
-1.43K-46.57-6.02-1.89-1.2
Price to sales ratio
00000
POCF ratio
-14.24K-72.52-6.8-2.07-1.66
PFCF ratio
-14.24K-61.61-6.14-1.93-1.48
P/B Ratio
-122.01-9.670.940.610.81
PTB ratio
-122.01-9.670.940.610.81
EV to sales
00000
Enterprise value over EBITDA
-9.41K-8.980.09-1.330.51
EV to operating cash flow
-14.36K-70.250.12-1.590.4
EV to free cash flow
-14.36K-59.680.11-1.480.36
Earnings yield
0-0.02-0.17-0.53-0.83
Free cash flow yield
0-0.02-0.16-0.52-0.68
Debt to equity
-0.9900.030.020
Debt to assets
367.500.030.020
Net debt to EBITDA
-75.830.295.170.42.62
Current ratio
00.6631.4421.1139.2
Interest coverage
-0.36-337.50-23.030
Income quality
0.170.130.750.870.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.180.110.070.12
Capex to revenue
00000
Capex to depreciation
0-12.77-7.82-2.8-4.51
Stock based compensation to revenue
00000
Graham number
0.214.1424.8414.6112.59
ROIC
3.870.04-0.13-0.33-0.4
Return on tangible assets
-31.5-0.6-0.15-0.3-0.66
Graham Net
-0.15-1.9912.424.423.17
Working capital
-2.22M-10.95M369.59M262.32M183.22M
Tangible asset value
-2.22M-65.41M384.05M296.29M183.58M
Net current asset value
-2.22M-66.87M363.8M249.75M183.15M
Invested capital
-0.9900.030.020
Average receivables
00000
Average payables
0315K1.54M2.53M1.43M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
01.9K1.22K114.0637.91
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00.190.33.29.63
Inventory turnover
00000
ROE
0.090.21-0.16-0.33-0.68
Capex per share
0-0.05-0.2-0.12-0.19

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.18
Net income per share
-0.4-0.38-0.97-0.39-0.4
Operating cash flow per share
-0.4-0.38-0.24-0.16-0.79
Free cash flow per share
-0.42-0.38-0.34-0.25-0.79
Cash per share
4.814.734.354.093.2
Book value per share
5.324.943.953.563.16
Tangible book value per share
5.324.943.953.563.16
Share holders equity per share
5.324.943.953.563.16
Interest debt per share
0.140.180.940.93-0.08
Market cap
1.29B958.08M1.03B993.99M1.06B
Enterprise value
1.25B892.81M957.8M864.11M878.37M
P/E ratio
-14.42-11.18-4.67-11.05-11.61
Price to sales ratio
0000103.93
POCF ratio
-57.74-45.46-75.63-105.73-23.19
PFCF ratio
-55.22-44.65-53.61-69.93-23.16
P/B Ratio
4.373.474.614.875.8
PTB ratio
4.373.474.614.875.8
EV to sales
000085.81
Enterprise value over EBITDA
-46.84-43.4356.07-34.53-60.75
EV to operating cash flow
-55.87-42.37-70.14-91.92-19.15
EV to free cash flow
-53.43-41.61-49.72-60.79-19.13
Earnings yield
-0.02-0.02-0.05-0.02-0.02
Free cash flow yield
-0.02-0.02-0.02-0.01-0.04
Debt to equity
0.020.020.240.260
Debt to assets
0.020.010.190.20
Net debt to EBITDA
1.573.17-4.395.1912.83
Current ratio
21.1118.8520.4719.0539.2
Interest coverage
-12.43-5.05002.79
Income quality
0.910.880.250.422
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00001.43
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.050.020.410.510
Capex to revenue
00000
Capex to depreciation
-1.5-0.59-6.61-6.32-0.35
Stock based compensation to revenue
00000.23
Graham number
6.946.539.315.615.3
ROIC
-0.08-0.08-0.28-0.080.03
Return on tangible assets
-0.07-0.07-0.19-0.08-0.12
Graham Net
4.354.123.2433.12
Working capital
262.32M255.97M238.9M226.25M183.22M
Tangible asset value
296.29M276.22M224.15M204.02M183.58M
Net current asset value
249.75M236.54M188.27M176.57M183.15M
Invested capital
0.020.020.240.260
Average receivables
00000
Average payables
3.29M2.3M2.36M3.24M2M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
105.6380.76116.68422.21158.45
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.851.110.770.210.57
Inventory turnover
00000
ROE
-0.08-0.08-0.25-0.11-0.12
Capex per share
-0.02-0.01-0.1-0.080

GRPH Frequently Asked Questions

What is Graphite Bio, Inc. stock symbol ?

Graphite Bio, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol GRPH

Is Graphite Bio, Inc. buy or a sell ?

5 stock analysts have 5 predictions with a medium analyst target price of $4.4. The lowest prediction is $2 and the highest is $7

What is GRPH stock prediction ?

What is Graphite Bio, Inc. stock quote today ?

Graphite Bio, Inc. stock price is $3.18 today.

Is Graphite Bio, Inc. stock public?

Yes, Graphite Bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap